SCHEMBL14764831

SCHEMBL14764831

CC1CCCCC1.O=S(=O)(Cl)Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.42
CA7 P43166 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA9 Q16790 1/20 0.42
KMT2A Q03164 2/20 0.39
EPHX1 P07099 1/20 0.38
CA1 P00915 4/20 0.36
CA2 P00918 3/20 0.35
CA4 P22748 1/20 0.35
ACHE P22303 2/20 0.34
MEN1 O00255 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
LMNA P02545 1/20 0.31
ADH1B P00325 1/20 0.30
ADH1C P00326 1/20 0.30
ADH1A P07327 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylcyclopentane SCHEMBL11593657 0.97 CA12 (0.39) CA12CA7CA14CA9KMT2A
SCHEMBL22495741 0.88 ACHE (0.42) CA12CA7CA14CA9KMT2A
SCHEMBL28353928 0.87 CA12 (0.38) CA12CA7CA14CA9KMT2A
SCHEMBL15617310 0.85 CA12 (0.37) CA12CA7CA14CA9KMT2A
SCHEMBL14999117 0.85 CA12 (0.37) CA12CA7CA14CA9KMT2A
SCHEMBL14845770 0.85 CA12 (0.37) CA12CA7CA14CA9KMT2A
SCHEMBL15457741 0.85 CA12 (0.37) CA12CA7CA14CA9KMT2A
SCHEMBL17570322 0.81 CA12 (0.33) CA12CA7CA14CA9KMT2A
SCHEMBL8216679 0.81
Cycloheptane SCHEMBL23885013 0.80 ACHE (0.43) CA12CA7CA14CA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116120261-A Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound 浙大宁波理工学院 2023-05-16 CN claimed
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. 2025-02-13 US disclosed
EP-4499609-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2025-02-05 EP disclosed
US-12187732-B2 Inhibitors of the myst family of lysine acetyl transferases Isosterix, Inc. (US) 2025-01-07 US disclosed
WO-2023192817-A9 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2024-10-03 WO disclosed
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases Isosterix, Inc. 2024-05-07 US disclosed
CN-116120261-B Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound 浙大宁波理工学院 2024-01-23 CN disclosed
US-20230416260-A1 Inhibitors of the MYST Family of Lysine Acetyl Transferases Isosterix, Inc. 2023-12-28 US disclosed
WO-2023192817-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES Isosterix, Inc. (US) 2023-10-05 WO disclosed
CN-116120261-A Preparation method of 3- [ (4-sulfadiazine-1-yl) methyl ] benzoic acid compound 浙大宁波理工学院 2023-05-16 CN disclosed
CN-101641348-B Imidazolidinone derivatives HOFFMANN LA ROCHE 2014-09-10 CN disclosed
EP-2576520-A1 RADIOLABELED COMPOUNDS AND METHODS THEREOF GE Healthcare UK Limited (GB) 2013-04-10 EP disclosed
US-20130064770-A1 RADIOLABELED COMPOUNDS AND METHODS THEREOF GE HEALTHCARE LIMITED (GB) 2013-03-14 US disclosed
CN-102918031-A Radiolabeled compounds and methods thereof GE HEALTHCARE LTD 2013-02-06 CN disclosed
WO-2011150183-A1 RADIOLABELED COMPOUNDS AND METHODS THEREOF GE HEALTHCARE LIMITED (GB) 2011-12-01 WO disclosed
CN-101641348-A Imidazolidinone derivatives HOFFMANN LA ROCHE CH 2010-02-03 CN disclosed
CN-101400651-A Diaryl piperidines as CB1 modulators SCHERING CORP (US) 2009-04-01 CN disclosed
CN-1756551-A New arylpiperazinyl compounds PREDIX PHARMACEUTICALS HOLDING (US) 2006-04-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051343-A1 INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES KAT6A, KAT6B, KAT2A CA12 4272/4885CA7 3349/4885CA14 4437/4885
US-20230416260-A1 Inhibitors of the MYST Family of Lysine Acetyl Transferases KAT6A, KAT6B, KAT2A CA12 4272/4885CA7 3349/4885CA14 4437/4885
US-12187732-B2 Inhibitors of the myst family of lysine acetyl transferases KAT6A, KAT6B, KAT2A CA12 4272/4885CA7 3349/4885CA14 4437/4885
US-20130064770-A1 RADIOLABELED COMPOUNDS AND METHODS THEREOF HTR5A, HTR3B, HTR1A CA12 1957/4885CA7 2985/4885CA14 1493/4885
US-11976075-B2 Inhibitors of the MYST family of lysine acetyl transferases KAT6A, KAT6B, KAT2A CA12 4272/4885CA7 3349/4885CA14 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.